List of Onglyza drug patents
Onglyza is owned by Astrazeneca Ab.
Onglyza contains Saxagliptin Hydrochloride.
Onglyza has a total of 2 drug patents out of which 0 drug patents have expired.
Onglyza was authorised for market use on 31 July, 2009.
Onglyza is available in tablet;oral dosage forms.
Onglyza can be used as method for treating type ii diabetes by administering saxagliptin; method for treating type ii diabetes mellitus by administering saxagliptin alone or in combination with insulin, metformin, a thiazolidinedione, glyburide or metformin plus a sulfonylurea.
The generics of Onglyza are possible to be released after 30 November, 2028.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| USRE44186 | ASTRAZENECA AB | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
Jul, 2023
(a month from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7951400 | ASTRAZENECA AB | Coated tablet formulation and method |
Nov, 2028
(5 years from now) | |
Drugs and Companies using SAXAGLIPTIN HYDROCHLORIDE ingredient
Market Authorisation Date: 31 July, 2009
Treatment: Method for treating type ii diabetes by administering saxagliptin; Method for treating type ii diabetes mellitus by administering saxagliptin alone or in combination with insulin, metformin, a thiazol...
Dosage: TABLET;ORAL
ONGLYZA family patents
7
United States
3
Spain
3
Slovenia
3
European Union
2
Israel
2
Croatia
2
Korea, Republic of
2
Denmark
2
ME
2
Cyprus
2
Portugal
2
Poland
2
Hong Kong
2
Argentina
2
RS
2
China
2
Hungary
2
Taiwan
1
Australia
1
Canada
1
New Zealand
1
Peru
1
Malaysia
1
Ukraine
1
Russia
1
Japan
1
Norway
1
Mexico
1
Georgia
1
Brazil
1
South Africa
1
Lithuania
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic